Search
Sensus Healthcare Inc
SRTSAdd to Watchlist
3.070USD
+0.040+1.32%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
50.54MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.32%
5 Days
+0.99%
1 Month
+8.87%
6 Months
-25.12%
Year to Date
-22.86%
1 Year
-34.12%
Key Figures
3.020Open
3.102High
20.94KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.13%Turnover Ratio
3.030Prev. Close
3.020Low
59.69KTurnover
7.60P/E Static
1.11P/B
0.00%Div Yield TTM
-13.91%ROA
5.92052wk High
0.93Volume Ratio
6.65MNet Profit
16.46MShares
-0.4749EPS TTM
1.12Beta
-15.77%ROE
2.82052wk Low
2.72%Amplitude
29.20%Gross Margin
50.54MMarket Cap
1.99Reward/Risk
3.74%Risk Rate
TradingKey Stock Score of Sensus Healthcare Inc
Currency: USD Updated: 2026-07-02Key Insights
Sensus Healthcare Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 91 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.75.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sensus Healthcare Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sensus Healthcare Inc Highlights
StrengthsRisks
Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.48M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -6.46, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.57M shares, decreasing 10.32% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
5.750
Target Price
+89.77%
Upside Space
Sensus Healthcare Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sensus Healthcare Inc Info
Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
Ticker SymbolSRTS
CompanySensus Healthcare Inc
CEOSardano (Joseph C)
Websitehttps://sensushealthcare.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Sensus Healthcare Inc (SRTS)?
The current price of Sensus Healthcare Inc (SRTS) is 3.07.
What is the symbol of Sensus Healthcare Inc?
The ticker symbol of Sensus Healthcare Inc is SRTS.
What is the 52-week high of Sensus Healthcare Inc?
The 52-week high of Sensus Healthcare Inc is 5.92.
What is the 52-week low of Sensus Healthcare Inc?
The 52-week low of Sensus Healthcare Inc is 2.82.
What is the market capitalization of Sensus Healthcare Inc?
The market capitalization of Sensus Healthcare Inc is 50.54M.
Is Sensus Healthcare Inc (SRTS) currently rated as Buy, Hold, or Sell?
According to analysts, Sensus Healthcare Inc (SRTS) has an overall rating of Buy, with a price target of 5.75.
What is the Earnings Per Share (EPS TTM) of Sensus Healthcare Inc (SRTS)?
The Earnings Per Share (EPS TTM) of Sensus Healthcare Inc (SRTS) is -0.47.